Title: Gene Silencing
Patent Number: 8,158,414
Filed: Sept. 23, 2005
Lead Inventor: Caius Rommens, JR Simplot

Opko Health said this week it has signed an exclusive deal with Laboratory Corporation of America for rights to Opko's Alzheimer's diagnostic technology.

Opko Health last month provided an update on its oligonucleotide medicines efforts, stating that it has programs in orphan neurologic and genetic disorders.

Opko Health said this week that it has expanded a licensing deal with Finnish biotech firm Artic Partners for prostate cancer protein biomarkers that it announced in January (

Opko Health said this week it has acquired an exclusive license from Finnish biotech firm Artic Partners for two biomarkers from the kallikrein protein family that could be used to diagnose prostate cancer.

Opko Health this week said it has agreed to sell its ophthalmic instrumentation business to Optos for $17.5 million in cash, plus royalties.
The transaction is slated to close in the fourth quarter.

Opko said it may use some of the proceeds to make additional acquisitions.

Opko Acquires Curna for $10M


Curna's technology, according to Opko, allows for the up-regulation of target proteins and was exclusively licensed from the Scripps Research Institute.

The company said that it will work with BMS to investigate the utility of its technology for diagnosis of Alzheimer's disease and for identifying individuals with early-stage cognitive impairment that are likely to progress to Alzheimer's disease.


An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.